Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SERAFA-1: A Single Arm, Open Label, Multicentre, Phase IIIb Study Of Camizestrant Plus Ribociclib in 1st Line Treatment of ER Positive, HER2-negative Advanced Breast Cancer Patients

NCT07647328 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT07647328
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07647328 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SERAFA-1: A Single Arm, Open Label, Multicentre, Phase IIIb Study Of Camizestrant Plus Ribociclib in 1st Line Treatment of ER Positive, HER2-negative Advanced Breast Cancer Patients
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Recruiting
Start date
June 15, 2026
Completion date
February 28, 2029
Enrollment
150 (estimated)
Sites
89

Conditions

As the registry lists them; a condition with its own page is linked.

er-positive her2-negative breast cancer